Prevalence and clinical manifestations of macrolide resistant pneumonia in Korean children

Original article Korean J Pediatr 2017;60(5):151-157 https://doi.org/10.3345/kjp.2017.60.5.151 pISSN 1738-1061•eISSN 2092-7258 Korean J Pediatr 2017;60(5):151-157 Korean J Pediatr Prevalence and clinical manifestations of ma crolide resistant Mycoplasma pneumoniae pneumonia in Korean children Eun Lee1, Hyun-Ju Cho2, Soo-Jong Hong2, Jina Lee2, Heungsup Sung3, Jinho Yu2 1 Department of Pediatrics, Chonnam National University Hospital, Gwangju, Departments of 2Pediatrics and 3Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Purpose: Macrolide resistance rate of Mycoplasma pneumoniae has rapidly increased in children. Studies on the clinical features between macrolide susceptible-M. pneumoniae (MSMP) and macrolide resistant-M. pneumoniae (MRMP) are lacking. The aim of this study was to identify the macrolide resistance rate of M. pneumoniae in Korean children with M. pneumoniae penupmonia in 2015 and compare manifestations between MSMP and MRMP. Methods: Among 122 children (0–18 years old) diagnosed with M. pneumoniae pneumonia, 95 children with the results of macrolide sensitivity test were included in this study. Clinical manifestations were acquired using retrospective medical records. Results: The macrolide resistant rate of M. pneumoniae was 87.2% (82 of 94 patients) in children with M. pneumoniae pneumonia. One patient showed a mixed type of wild type and A2063G mutation in 23S rRNA of M. pneumoniae. There were no significant differences in clinical, laboratory, and radiologic findings between the MSMP and MRMP groups at the first visit to our hospital. The time interval between initiation of macrolide and defervescence was significantly longer in the MRMP group (4.9±3.3 vs. 2.8±3.1 days, P=0.039). Conclusion: The macrolide resistant rate of M. pneumoniae is very high in children with M. pneumoniae pneumonia in Korea. The clinical manifestations of MRMP are similar to MSMP except for the deferve scence period after administration of macrolide. Continuous monitoring of the occurrence and antimi crobial susceptibility of MRMP is required to control its spread and establish strategies for treating second-line antibiotic resistant M. pneumoniae infection. Corresponding author: Jinho Yu, MD, PhD Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea Tel: +82-2-3010-3922 Fax: +82-2-473-3725 E-mail: Co-corresponding author: Heungsup Sung, MD, PhD Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea Tel: +82-2-3010-4499 Fax: +82-2-2045-4081 E-mail: Received: 8 September, 2016 Revised: 1 December, 2016 Accepted: 21 December, 2016 Key words: Child, Macrolide, Mycoplasma pneumoniae, Drug resistance Introduction Mycoplasma pneumoniae can cause a variety of respiratory tract diseases, such as upper respiratory infection and atypical pneumonia1). The clinical course of M. pneumoniae infection is diverse and ranges from self-limiting to severe pneumonia with extrapul monary complications2). Among the diverse clinical presentations, lower respiratory tract infections with pneumonia most commonly require clinical attention. Macrolide is considered the first-line treatment for M. pneumoniae infection3). Transi tional mutations in 23S rRNA of M. pneumoniae were reported in erythromycin-resistant M. pneumoniae in 1995.4) Thereafter, especially since 2000, the prevalence of macrolideresistant M. pneumoniae (MRMP) infection has rapidly increased, with variations according to region and study population5). The macrolide resistance rate of M. pneumoniae is much Copyright © 2017 by The Korean Pediatric Society This is an open-access article distributed under the terms of the Creative Commons Attribution NonCommercial License (http://creativecommons.org/ licenses/by-nc/4.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited. https://doi.org/10.3345/kjp.2017.60.5.151 151 Lee E, et al. • Macrolide-resistant Mycoplasma pneumoniae pneumonia higher in East Asia than in Europe and North America, with up to 87.1% in Japanese children in 20115-8). In recent M. pneumoniae epidemics in Korea, the macrolide resistance rate has markedly increased from 2.9% in 2003 to 62.9% in 20115). In cases of MRMP infection, secondary treatment options are limited due to adverse effects of tetracycline or fluoroquinolones, especially in children9). In addition, resistance to second-line therapy is a concern given the rapid increase in MRMP preval ence. Therefore, continuous survey on the prevalence of MRMP and surveillance on the prescription for M. pneumoniae are in evitably needed in the prevailing state of MRMP. Previous studies comparing the clinical manifestations of macrolide susceptible M. pneumoniae (MSMP) and MRMP show ed inconclusive results10-13). Although a high macrolide resistance rate of M. pneumoniae has been reported, studies on the treat ment patterns of MRMP pneumonia in children are lacking. Fur ther investigation is needed to develop appropriate treatment strategies and monitor the emergence of second-line therapy resistant M. pneumoniae. The aim of this study was to identify the prevalence of macro lide resistance in children with M. pneumoniae pneumonia in 2015 and compare the clinical features and treatment patterns of MSMP and MRMP in these children. Materials and methods 1. Study population This study enrolled patients aged between 0–18 years old, who were diagnosed with community-acquired pneumonia due to M. pneumoniae who visited our tertiary hospital in Seoul between April 2015 and November 2015. All of the present study patients underwent chest radiography and either blood tests including specific IgM against M. pneumoniae using a LIAISON Mycoplas ma pneumoniae IgM kit (DiaSorin, Dublin, Ireland) or polymerase chain reaction (PCR) for M. pneumoniae using the AmpliSens Mycoplasma pneumoniae/Chlamydia pneumoniae-FRT PCR kit (InterLabService Ltd., Moscow, Russia) at the initial visit to the hospital. During the study period, 122 children were diagnosed with M. pneumoniae pneumonia on the basis of either specific IgM positivity in a blood test or positive PCR result combined with chest radiography and physical examination14). Four children re ceived only serologic testing for specific IgM against M. pneu moniae and showed positivity. Eight children underwent only PCR analysis of their sputum for M. pneumoniae and showed a positive result. Ninety-two children showed both specific IgM and PCR positivity for M. pneumoniae. The remaining 18 children were tested for both specific IgM and PCR for M. pneumoniae, but showed a positive result only for PCR. Among the 118 152 https://doi.org/10.3345/kjp.2017.60.5.151 children with positive result by PCR for M. pneumoniae, mac (...truncated)